FDA places clinical hold on vTv Therapeutics' cadisegliatin Phase 3 trial for type 1 diabetes

vTv Therapeutics Inc.

FDA clinical hold based on unresolved chromatographic signal in cadisegliatin ADME study.
FDA requires a single in vitro study to characterize signal before program can resume.
No patients had been dosed in CATT1 Phase 3 trial at time of hold; no prior safety issues.
vTv is working with FDA to resolve hold and resume enrollment as quickly as possible.
Cadisegliatin is an oral glucokinase activator; over 500 subjects dosed to date with favorable safety profile.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.